Memorial Sloan Kettering Cancer Center

New treatments for emerging targets have expanded the armamentarium in lung cancer, according to a speaker at Chemotherapy Foundation Symposium.

The American Society for Radiation Oncology presented the ASTRO Gold Medal to two of its members.

A study presented at this year’s ASCO Quality Care Symposium examined predictors of compliance with payer-led oncology clinical pathways.

The FDA granted accelerated approval to cobimetinib for treatment of certain patients of histiocytic neoplasms.

BOSTON — Excisional biopsies of soft tissue sarcoma of the hand are associated with more positive margins and a longer time to patients’ first intervention vs. incisional/needle biopsies, results of a study showed.

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.

A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer.

Since the beginning of her career, Fumiko Chino, MD, has rooted her work as a radiation oncologist in the patient experience, continually working to improve optimal care for those with cancer.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.